Originally Posted by
NT001
No of course I don't have "numbers" myself, but DD has given some, for example in his online shareholder presentation. They indicate there's a worthwhile number of potential patients. But those who appear to oppose any attempt to open up this market would demand far more than that, including precise details of how much will be earned (net) for each test done, etc, and the air fares involved. Apart from the fact that much of this would be commercially sensitive, how would I possibly know? Can you name a company that submits "numbers" publicly to its shareholders for any new deal before going ahead with it?
Some contributors on this thread are steadfastly opposed to anything that DD does and have hangups about him claiming expenses for an air fare, but I am in PEB for a longer haul, not instant 100% success. If I had no confidence in the competence of PEB's management I obviously wouldn't be holding its shares.
DD has also made the point that taking up the Singapore opportunity has other potential benefits in terms of exposure of PEB's product and experience in international markets other than the US. The US market is potentially big but it's not necessarily a model for developing markets elsewhere.
I simply don't accept the notion that until PEB has begun reporting net positive returns from that market, which may yet take a year or two or three for all I know (and may conceivably not happen at all if other products beat Cxbladder in the race for acceptance), it should turn a completely blind eye to all other opportunities elsewhere. What's the rationale for that?